Daiwa Sticks to Their Sell Rating for Astellas Pharma (ALPMF)
In a report released today, from Daiwa maintained a Sell rating on Astellas Pharma, with a price target of Yen1,600.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The word on The Street in general, suggests a Hold analyst consensus rating for Astellas Pharma with a Yen2,103.66 average price target.
Based on Astellas Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of Yen524.32 billion and a net profit of Yen79.21 billion. In comparison, last year the company earned a revenue of Yen462.5 billion and had a net profit of Yen35.91 billion
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.